Literature DB >> 9457429

Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia.

M Denton1, K G Kerr.   

Abstract

The gram-negative bacterium Stenotrophomonas maltophilia is increasingly recognized as an important cause of nosocomial infection. Infection occurs principally, but not exclusively, in debilitated and immunosuppressed individuals. Management of S. maltophilia-associated infection is problematic because many strains of the bacterium manifest resistance to multiple antibiotics. These difficulties are compounded by methodological problems in in vitro susceptibility testing for which there are, as yet, no formal guidelines. Despite its acknowledged importance as a nosocomial pathogen, little is known of the epidemiology of S. maltophilia, and although it is considered an environmental bacterium, its sources and reservoirs are often not readily apparent. Molecular typing systems may contribute to our knowledge of the epidemiology of S. maltophilia infection, thus allowing the development of strategies to interrupt the transmission of the bacterium in the hospital setting. Even less is known of pathogenic mechanisms and putative virulence factors involved in the natural history of S. maltophilia infection and this, coupled with difficulties in distinguishing colonization from true infection, has fostered the view that the bacterium is essentially nonpathogenic. This article aims to review the current taxonomic status of S. maltophilia, and it discusses the laboratory identification of the bacterium. The epidemiology of the organism is considered with particular reference to nosocomial outbreaks, several of which have been investigated by molecular typing techniques. Risk factors for acquisition of the bacterium are also reviewed, and the ever-expanding spectrum of clinical syndromes associated with S. maltophilia is surveyed. Antimicrobial resistance mechanisms, pitfalls in in vitro susceptibility testing, and therapy of S. maltophilia infections are also discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9457429      PMCID: PMC121376          DOI: 10.1128/CMR.11.1.57

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  394 in total

1.  Changes in the spectrum of organisms causing bacteremia and fungemia in immunocompromised patients due to venous access devices.

Authors:  T E Kiehn; D Armstrong
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-12       Impact factor: 3.267

2.  In-vitro pharmacodynamic studies of piperacillin/tazobactam with gentamicin and ciprofloxacin.

Authors:  I M Gould; K Milne
Journal:  J Antimicrob Chemother       Date:  1997-01       Impact factor: 5.790

3.  Fast-growing, aerobic, heterotrophic bacteria from the rhizosphere of young sugar beet plants.

Authors:  B Lambert; P Meire; H Joos; P Lens; J Swings
Journal:  Appl Environ Microbiol       Date:  1990-11       Impact factor: 4.792

4.  AXanthomonas maltophilia isolate tolerating up to 1% sodium azide in Tris/HCl buffer.

Authors:  J J Borowicz; S Brishammar; B Gerhardson
Journal:  World J Microbiol Biotechnol       Date:  1995-03       Impact factor: 3.312

5.  DNA restriction fragment length polymorphism differentiates crossed from independent infections in nosocomial Xanthomonas maltophilia bacteremia.

Authors:  E H Bingen; E Denamur; N Y Lambert-Zechovsky; A Bourdois; P Mariani-Kurkdjian; J P Cezard; J Navarro; J Elion
Journal:  J Clin Microbiol       Date:  1991-07       Impact factor: 5.948

6.  [Molecular typing by pulsed field gel electrophoresis of Stenotrophomonas maltophilia isolated in a department of hematology].

Authors:  C Fabe; P Rodriguez; P Cony-Makhoul; P Parneix; C Bebear; J Maugein
Journal:  Pathol Biol (Paris)       Date:  1996-05

7.  Diversity of nosocomial Xanthomonas maltophilia (Stenotrophomonas maltophilia) as determined by ribotyping.

Authors:  P Gerner-Smidt; B Bruun; M Arpi; J Schmidt
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-02       Impact factor: 3.267

Review 8.  Isepamicin (SCH 21420, 1-N-HAPA gentamicin B): microbiological characteristics including antimicrobial potency of spectrum of activity.

Authors:  R N Jones
Journal:  J Chemother       Date:  1995-06       Impact factor: 1.714

9.  In vitro activity of sparfloxacin (CI-978), a new broad-spectrum fluoroquinolone.

Authors:  S M Qadri; Y Ueno; J J Burns; E Almodovar; N Rabea
Journal:  Chemotherapy       Date:  1992       Impact factor: 2.544

10.  The bacteriology of obstructive pneumonitis. A prospective study using ultrasound-guided transthoracic needle aspiration.

Authors:  Y S Liaw; P C Yang; Z G Wu; C J Yu; D B Chang; L N Lee; S H Kuo; K T Luh
Journal:  Am J Respir Crit Care Med       Date:  1994-06       Impact factor: 21.405

View more
  210 in total

1.  Antimicrobial susceptibilities of unique Stenotrophomonas maltophilia clinical strains.

Authors:  S Valdezate; A Vindel; E Loza; F Baquero; R Cantón
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

2.  Stenotrophomonas maltophilia D457R contains a cluster of genes from gram-positive bacteria involved in antibiotic and heavy metal resistance.

Authors:  A Alonso; P Sanchez; J L Martínez
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

3.  Community analysis of biofilters using fluorescence in situ hybridization including a new probe for the Xanthomonas branch of the class Proteobacteria.

Authors:  U Friedrich; M M Naismith; K Altendorf; A Lipski
Journal:  Appl Environ Microbiol       Date:  1999-08       Impact factor: 4.792

Review 4.  Taxonomy and identification of the Burkholderia cepacia complex.

Authors:  T Coenye; P Vandamme; J R Govan; J J LiPuma
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

5.  Expression of multidrug efflux pump SmeDEF by clinical isolates of Stenotrophomonas maltophilia.

Authors:  A Alonso; J L Martinez
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

6.  Antimicrobial activities of gatifloxacin against nosocomial isolates of Stenotrophomonas maltophilia measured by MIC and time-kill studies.

Authors:  M L Cohn; K B Waites
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

7.  Contribution of resistance-nodulation-division efflux pump operon smeU1-V-W-U2-X to multidrug resistance of Stenotrophomonas maltophilia.

Authors:  Chao-Hsien Chen; Chiang-Ching Huang; Tsao-Chuen Chung; Rouh-Mei Hu; Yi-Wei Huang; Tsuey-Ching Yang
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

8.  Class 1 integrons increase trimethoprim-sulfamethoxazole MICs against epidemiologically unrelated Stenotrophomonas maltophilia isolates.

Authors:  Raquel Barbolla; Mariana Catalano; Betina E Orman; Angela Famiglietti; Carlos Vay; Jorgelina Smayevsky; Daniela Centrón; Silvia A Piñeiro
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

9.  Molecular detection of transcriptionally active bacteria from failed prosthetic hip joints removed during revision arthroplasty.

Authors:  M P Riggio; Kate E Dempsey; Allan Lennon; David Allan; Gordon Ramage; Jeremy Bagg
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-05-08       Impact factor: 3.267

10.  Isolation and characterization of novel giant Stenotrophomonas maltophilia phage phiSMA5.

Authors:  Hsiao-Chuan Chang; Chiy-Rong Chen; Juey-Wen Lin; Gwan-Han Shen; Kai-Ming Chang; Yi-Hsiung Tseng; Shu-Fen Weng
Journal:  Appl Environ Microbiol       Date:  2005-03       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.